Both Lazcluze and Rybrevant specifically target EGFR mutations that drive tumour growth in certain types of NSCLC. Tagrisso – ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

This phase 1a/b dose escalation study examined zongertinib in patients with HER2 mutation-positive NSCLC.

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...